ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers

Alexander Augustyn, Mark Borromeo, Tao Wang, Junya Fujimoto, Chunli Shao, Patrick D. Dospoy, Victoria Lee, Christopher Tan, James P. Sullivan, Jill E. Larsen, Luc Girard, Carmen Behrens, Ignacio I. Wistuba, Yang Xie, Melanie H. Cobb, Adi F. Gazdar, Jane E. Johnson, John D. Minna

Research output: Contribution to journalArticle

Abstract

Aggressive neuroendocrine lung cancers, including small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), represent an understudied tumor subset that accounts for approximately 40,000 new lung cancer cases per year in the United States. No targeted therapy exists for these tumors. We determined that achaete-scute homolog 1 (ASCL1), a transcription factor required for proper development of pulmonary neuroendocrine cells, is essential for the survival of a majority of lung cancers (both SCLC and NSCLC) with neuroendocrine features. By combining whole-genome microarray expression analysis performed on lung cancer cell lines with ChIP-Seq data designed to identify conserved transcriptional targets of ASCL1, we discovered an ASCL1 target 72-gene expression signature that (i) identifies neuroendocrine differentiation in NSCLC cell lines, (ii) is predictive of poor prognosis in resected NSCLC specimens from three datasets, and (iii) represents novel "druggable" targets. Among these druggable targets is B-cell CLL/lymphoma 2, which when pharmacologically inhibited stops ASCL1-dependent tumor growth in vitro and in vivo and represents a proof-of-principle ASCL1 downstream target gene. Analysis of downstream targets of ASCL1 represents an important advance in the development of targeted therapy for the neuroendocrine class of lung cancers, providing a significant step forward in the understanding and therapeutic targeting of the molecular vulnerabilities of neuroendocrine lung cancer.

Original languageEnglish (US)
Pages (from-to)14788-14793
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume111
Issue number41
DOIs
StatePublished - Oct 14 2014

Fingerprint

Oncogenes
Lung Neoplasms
Non-Small Cell Lung Carcinoma
Small Cell Lung Carcinoma
Therapeutics
Cell Line
Neoplasms
Neuroendocrine Cells
B-Cell Lymphoma
Microarray Analysis
Transcriptome
Transcription Factors
Genome
Lung
Growth
Genes

Keywords

  • ASCL1 transcriptome
  • personalized therapy
  • target discovery

ASJC Scopus subject areas

  • Medicine(all)

Cite this

ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. / Augustyn, Alexander; Borromeo, Mark; Wang, Tao; Fujimoto, Junya; Shao, Chunli; Dospoy, Patrick D.; Lee, Victoria; Tan, Christopher; Sullivan, James P.; Larsen, Jill E.; Girard, Luc; Behrens, Carmen; Wistuba, Ignacio I.; Xie, Yang; Cobb, Melanie H.; Gazdar, Adi F.; Johnson, Jane E.; Minna, John D.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 111, No. 41, 14.10.2014, p. 14788-14793.

Research output: Contribution to journalArticle

Augustyn, Alexander ; Borromeo, Mark ; Wang, Tao ; Fujimoto, Junya ; Shao, Chunli ; Dospoy, Patrick D. ; Lee, Victoria ; Tan, Christopher ; Sullivan, James P. ; Larsen, Jill E. ; Girard, Luc ; Behrens, Carmen ; Wistuba, Ignacio I. ; Xie, Yang ; Cobb, Melanie H. ; Gazdar, Adi F. ; Johnson, Jane E. ; Minna, John D. / ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. In: Proceedings of the National Academy of Sciences of the United States of America. 2014 ; Vol. 111, No. 41. pp. 14788-14793.
@article{6f7162e1b82d48e5b7b9c7c0faa5fd6b,
title = "ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers",
abstract = "Aggressive neuroendocrine lung cancers, including small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), represent an understudied tumor subset that accounts for approximately 40,000 new lung cancer cases per year in the United States. No targeted therapy exists for these tumors. We determined that achaete-scute homolog 1 (ASCL1), a transcription factor required for proper development of pulmonary neuroendocrine cells, is essential for the survival of a majority of lung cancers (both SCLC and NSCLC) with neuroendocrine features. By combining whole-genome microarray expression analysis performed on lung cancer cell lines with ChIP-Seq data designed to identify conserved transcriptional targets of ASCL1, we discovered an ASCL1 target 72-gene expression signature that (i) identifies neuroendocrine differentiation in NSCLC cell lines, (ii) is predictive of poor prognosis in resected NSCLC specimens from three datasets, and (iii) represents novel {"}druggable{"} targets. Among these druggable targets is B-cell CLL/lymphoma 2, which when pharmacologically inhibited stops ASCL1-dependent tumor growth in vitro and in vivo and represents a proof-of-principle ASCL1 downstream target gene. Analysis of downstream targets of ASCL1 represents an important advance in the development of targeted therapy for the neuroendocrine class of lung cancers, providing a significant step forward in the understanding and therapeutic targeting of the molecular vulnerabilities of neuroendocrine lung cancer.",
keywords = "ASCL1 transcriptome, personalized therapy, target discovery",
author = "Alexander Augustyn and Mark Borromeo and Tao Wang and Junya Fujimoto and Chunli Shao and Dospoy, {Patrick D.} and Victoria Lee and Christopher Tan and Sullivan, {James P.} and Larsen, {Jill E.} and Luc Girard and Carmen Behrens and Wistuba, {Ignacio I.} and Yang Xie and Cobb, {Melanie H.} and Gazdar, {Adi F.} and Johnson, {Jane E.} and Minna, {John D.}",
year = "2014",
month = "10",
day = "14",
doi = "10.1073/pnas.1410419111",
language = "English (US)",
volume = "111",
pages = "14788--14793",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "41",

}

TY - JOUR

T1 - ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers

AU - Augustyn, Alexander

AU - Borromeo, Mark

AU - Wang, Tao

AU - Fujimoto, Junya

AU - Shao, Chunli

AU - Dospoy, Patrick D.

AU - Lee, Victoria

AU - Tan, Christopher

AU - Sullivan, James P.

AU - Larsen, Jill E.

AU - Girard, Luc

AU - Behrens, Carmen

AU - Wistuba, Ignacio I.

AU - Xie, Yang

AU - Cobb, Melanie H.

AU - Gazdar, Adi F.

AU - Johnson, Jane E.

AU - Minna, John D.

PY - 2014/10/14

Y1 - 2014/10/14

N2 - Aggressive neuroendocrine lung cancers, including small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), represent an understudied tumor subset that accounts for approximately 40,000 new lung cancer cases per year in the United States. No targeted therapy exists for these tumors. We determined that achaete-scute homolog 1 (ASCL1), a transcription factor required for proper development of pulmonary neuroendocrine cells, is essential for the survival of a majority of lung cancers (both SCLC and NSCLC) with neuroendocrine features. By combining whole-genome microarray expression analysis performed on lung cancer cell lines with ChIP-Seq data designed to identify conserved transcriptional targets of ASCL1, we discovered an ASCL1 target 72-gene expression signature that (i) identifies neuroendocrine differentiation in NSCLC cell lines, (ii) is predictive of poor prognosis in resected NSCLC specimens from three datasets, and (iii) represents novel "druggable" targets. Among these druggable targets is B-cell CLL/lymphoma 2, which when pharmacologically inhibited stops ASCL1-dependent tumor growth in vitro and in vivo and represents a proof-of-principle ASCL1 downstream target gene. Analysis of downstream targets of ASCL1 represents an important advance in the development of targeted therapy for the neuroendocrine class of lung cancers, providing a significant step forward in the understanding and therapeutic targeting of the molecular vulnerabilities of neuroendocrine lung cancer.

AB - Aggressive neuroendocrine lung cancers, including small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), represent an understudied tumor subset that accounts for approximately 40,000 new lung cancer cases per year in the United States. No targeted therapy exists for these tumors. We determined that achaete-scute homolog 1 (ASCL1), a transcription factor required for proper development of pulmonary neuroendocrine cells, is essential for the survival of a majority of lung cancers (both SCLC and NSCLC) with neuroendocrine features. By combining whole-genome microarray expression analysis performed on lung cancer cell lines with ChIP-Seq data designed to identify conserved transcriptional targets of ASCL1, we discovered an ASCL1 target 72-gene expression signature that (i) identifies neuroendocrine differentiation in NSCLC cell lines, (ii) is predictive of poor prognosis in resected NSCLC specimens from three datasets, and (iii) represents novel "druggable" targets. Among these druggable targets is B-cell CLL/lymphoma 2, which when pharmacologically inhibited stops ASCL1-dependent tumor growth in vitro and in vivo and represents a proof-of-principle ASCL1 downstream target gene. Analysis of downstream targets of ASCL1 represents an important advance in the development of targeted therapy for the neuroendocrine class of lung cancers, providing a significant step forward in the understanding and therapeutic targeting of the molecular vulnerabilities of neuroendocrine lung cancer.

KW - ASCL1 transcriptome

KW - personalized therapy

KW - target discovery

UR - http://www.scopus.com/inward/record.url?scp=84965087302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965087302&partnerID=8YFLogxK

U2 - 10.1073/pnas.1410419111

DO - 10.1073/pnas.1410419111

M3 - Article

VL - 111

SP - 14788

EP - 14793

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 41

ER -